Taken together, these findings demonstrate the potent synergy of PDT and STING agonists in nanosystems, offering a transformative strategy to overcome tumor immune suppression, enhance systemic antitumor immunity, and achieve superior therapeutic outcomes in cancer immunotherapy. Here, STING1 is linked to cancer.